Idiopathic inflammatory myopathies
IE Lundberg, M Fujimoto, J Vencovsky… - Nature Reviews …, 2021 - nature.com
Idiopathic inflammatory myopathies (IIM), also known as myositis, are a heterogeneous
group of autoimmune disorders with varying clinical manifestations, treatment responses …
group of autoimmune disorders with varying clinical manifestations, treatment responses …
Current classification and management of inflammatory myopathies
J Schmidt - Journal of neuromuscular diseases, 2018 - content.iospress.com
Inflammatory disorders of the skeletal muscle include polymyositis (PM), dermatomyositis
(DM),(immune mediated) necrotizing myopathy (NM), overlap syndrome with myositis …
(DM),(immune mediated) necrotizing myopathy (NM), overlap syndrome with myositis …
CD19 CAR T-cell therapy in autoimmune disease—a case series with follow-up
F Müller, J Taubmann, L Bucci, A Wilhelm… - … England Journal of …, 2024 - Mass Medical Soc
Background Treatment for autoimmune diseases such as systemic lupus erythematosus
(SLE), idiopathic inflammatory myositis, and systemic sclerosis often involves long-term …
(SLE), idiopathic inflammatory myositis, and systemic sclerosis often involves long-term …
[HTML][HTML] Trial of intravenous immune globulin in dermatomyositis
R Aggarwal, C Charles-Schoeman… - … England Journal of …, 2022 - Mass Medical Soc
Background Intravenous immune globulin (IVIG) for the treatment of dermatomyositis has not
been extensively evaluated. Methods We conducted a randomized, placebo-controlled trial …
been extensively evaluated. Methods We conducted a randomized, placebo-controlled trial …
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
X Wang, X Wu, B Tan, L Zhu, Y Zhang, L Lin, Y Xiao… - Cell, 2024 - cell.com
Allogeneic chimeric antigen receptor (CAR)-T cells hold great promise for expanding the
accessibility of CAR-T therapy, whereas the risks of allograft rejection have hampered its …
accessibility of CAR-T therapy, whereas the risks of allograft rejection have hampered its …
Study of tofacitinib in refractory dermatomyositis: an open‐label pilot study of ten patients
Objective This open‐label 12‐week study was conducted to evaluate the efficacy and safety
of tofacitinib, a JAK inhibitor, in treatment‐refractory active dermatomyositis (DM). Methods …
of tofacitinib, a JAK inhibitor, in treatment‐refractory active dermatomyositis (DM). Methods …
239th ENMC international workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018
Idiopathic inflammatory myopathies (IIM) are a heterogenous family of diseases that can
affect the muscles, skin, lungs, and joints. There have been prior attempts to classify IIMs …
affect the muscles, skin, lungs, and joints. There have been prior attempts to classify IIMs …
Treatment in myositis
CV Oddis, R Aggarwal - Nature Reviews Rheumatology, 2018 - nature.com
As with the treatment of many immune-mediated diseases, managing myositis encompasses
diverse factors, which present a challenge to the physician caring for these patients. The …
diverse factors, which present a challenge to the physician caring for these patients. The …
Update on outcome assessment in myositis
The adult and juvenile myositis syndromes, commonly referred to collectively as idiopathic
inflammatory myopathies (IIMs), are systemic autoimmune diseases with the hallmarks of …
inflammatory myopathies (IIMs), are systemic autoimmune diseases with the hallmarks of …
Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial
A Tjärnlund, Q Tang, C Wick, M Dastmalchi… - Annals of the …, 2018 - ard.bmj.com
Objectives To study the effects of abatacept on disease activity and on muscle biopsy
features of adult patients with dermatomyositis (DM) or polymyositis (PM). Methods Twenty …
features of adult patients with dermatomyositis (DM) or polymyositis (PM). Methods Twenty …